xerodent 0.25 mg / 28.6 mg imeskelytabletti
actavis group ehf. - natrii fluoridum,happo malicum - imeskelytabletti - 0.25 mg / 28.6 mg - natriumfluoridi, yhdistelmävalmisteet
tambocor retard 100 mg depotkapseli, kova
viatris oy - flecainide acetate - depotkapseli, kova - 100 mg - flekainidi
tambocor retard 200 mg depotkapseli, kova
viatris oy - flecainide acetate - depotkapseli, kova - 200 mg - flekainidi
codetabs imeskelytabletti
orifarm healthcare a/s - cocillana cortex extr spirit fluid (2:1) - imeskelytabletti - yskänhillitsijät ja ekspektorantit
fludent anis 0.25 mg f imeskelytabletti
actavis group ehf. - natrii fluoridum - imeskelytabletti - 0.25 mg f - natriumfluoridi
fludent hallon 0.25 mg f imeskelytabletti
actavis group ehf. - natrii fluoridum - imeskelytabletti - 0.25 mg f - natriumfluoridi
crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - lääkkeet luusairauksien hoitoon - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.
poteligeo
kyowa kirin holdings b.v. - mogamulizumab - sezary syndrome; mycosis fungoides - antineoplastiset aineet - poteligeo on tarkoitettu aikuisille potilaille, joilla on t-solulymfooman (mf) tai sézary oireyhtymä (ss), jotka ovat saaneet vähintään yksi aikaisempi systeeminen hoito.